Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of “Buy” by Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and five have assigned a strong buy rating to the company.

ZLDPF has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th.

Zealand Pharma A/S Price Performance

Shares of ZLDPF opened at $63.84 on Wednesday. The firm has a fifty day moving average price of $70.07 and a 200 day moving average price of $70.37. The stock has a market cap of $4.53 billion, a PE ratio of 4.59 and a beta of 0.73. Zealand Pharma A/S has a 1-year low of $49.98 and a 1-year high of $108.30. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. The firm had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%. As a group, sell-side analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.